Navigation Links
Takeda to Acquire Inviragen, Inc.
Date:5/7/2013

n>Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Takeda's Vaccine Business Division
Takeda has a proven track record of manufacturing and supplying vaccines in Japan for more than sixty years. Takeda's global vaccine business division was launched in January 2012 to build upon this success, and is headquartered in Deerfield, Illinois. The company acquired LigoCyte Pharmaceuticals and its norovirus vaccine candidate, as well as its proprietary virus-like particle vaccine platform and several preclinical vaccine candidates in October 2012.

About EDBI
EDBI is a leading strategic investment firm headquartered in Singapore with a worldwide presence investing to drive growth opportunities within the knowledge and innovation-intensive sectors of Biomedical Sciences (through its subsidiary Bio*One Capital), Clean Technologies, Internet & Digital Media, as well as key industries in Singapore. As a value adding investor, EDBI creates sustainable and synergistic partnerships with its portfolio companies, leveraging on its extensive networks and experience to facilitate the companies' growth in Asia and the world, through their operations in Singapore.
Please visit: www.edbi.com.

Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals re
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Responds to Verdict in Diabetes Drug Case
2. Takeda Launches New Subsidiary in Ecuador
3. Takeda lanza nueva subsidiaria en Ecuador
4. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
5. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
6. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
7. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
10. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
11. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... SPRINGS, Colo. , Aug. 22, 2014 /PRNewswire/ ... specializing in cannabis formulation-based drug development and related ... UFCM iCare,s third international medical cannabis conference taking ... Strasbourg, France , on October 22, ... with other stakeholders, such as researchers, health professionals, ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... -- Phase II,results exceed expectations - Alchemia prepares ... company Alchemia Limited will,commence discussions with the US ... of the Phase II clinical trial,of its metastatic ... from the randomized Phase II clinical trial in ...
... data on Eloxatin(R), Taxotere(R) and on three investigational,agents ... at the 43rd,annual ASCO meeting, BRIDGEWATER, N.J., May ... total of 375 abstracts,indicative of its oncology commitment ... the American Society of Clinical Oncology,(ASCO) in Chicago, ...
Cached Medicine Technology:Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 2Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 3Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:8/23/2014)... (PRWEB) August 23, 2014 Having been in ... dental hygienist from Arlington, Texas, saw a need for an ... toothpaste. "That’s when I came up with the idea for ... provides an effective way for a user to clean the ... to carry multiple items. It also helps avoid plaque buildup ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Hundreds ... filed on behalf of individuals who were allegedly ... replacement line continue to move forward in the ... Liebhard LLP reports. According to an Order dated ... trial program that would allow the litigation’s first ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Youth substance abuse is a serious problem across ... TX. Substance abuse can happen to people of all ... dependency in higher numbers than ever before. Many ... don’t know where to find professional youth rehab. ... because most treatment options are designed for adults. The ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... Md., May 8 Micromet, Inc. (Nasdaq:,MITI), a biopharmaceutical ... the treatment of cancer, inflammation and,autoimmune diseases, today announced ... 2008., Summary of Recent Events:, -- ... phase 1 clinical trial with ...
... Sciences,Inc. (Nasdaq: HGSI ) today announced that John ... of Pfizer Global Research and,Development, has been appointed to ... ), "We are honored to have John ... President and Chief Executive Officer, HGS. "John,s,record of accomplishment ...
... Ortho Organizers, Inc., a,leading manufacturer of orthodontic ... of their new premium O2 Select Orthodontic,Instruments., ... Organizers President and CEO George W. Guttroff ... with the release of O2 Select,Orthodontic Instruments. ...
... than $8 million for medicines and other lifesaving ... ... death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely concerned that the ... increase the death toll among children and other,vulnerable populations, leading to a ...
... Calif., May 8 Samplify Systems, Inc., a,real-time ... Crawford, a leading expert in computed tomography, has ... of experience in the,architecture, design, and development of ... "We are delighted to add Carl,s knowledge of ...
... Hospital buildings can heal,according to the first ... the,physical environment on child patients in health care ... through the,Physical Environment is produced by the National ... partnership with the Center,for Health Design. Findings from ...
Cached Medicine News:Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 9Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 2Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 3Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 4Health News:Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments 2Health News:Myanmar Cyclone a Children's Catastrophe - UNICEF 2Health News:Samplify Systems Adds Computed Tomography Expert Carl Crawford to Technical Team 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: